# A Study Comparing Siplizumab With Rabbit Anti-Thymocyte Globulin to Help the Body Accept a Kidney Transplant

> **NCT07508787** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Nefro Avillion Clinical Development, LLC** · enrollment: 120 (estimated)

## Conditions studied

- Renal Transplant Failure and Rejection

## Interventions

- **DRUG:** Siplizumab
- **DRUG:** Rabbit anti-thymocyte globulin

## Key facts

- **NCT ID:** NCT07508787
- **Lead sponsor:** Nefro Avillion Clinical Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-29
- **Primary completion:** 2028-03-28
- **Final completion:** 2028-03-28
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07508787

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07508787, "A Study Comparing Siplizumab With Rabbit Anti-Thymocyte Globulin to Help the Body Accept a Kidney Transplant". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07508787. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*